4.0798

2.78% 0.1198

Prime Medicine Inc (PRME)

Overview News Price History Option Chain Financials Discussions Forecast

Prime Medicine Inc stock is traded at $4.0798, with a volume of 371.82K. It is up +2.78% in the last 24 hours and up +15.95% over the past month. Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Previous Close:

$3.96

Open:

$3.89

24h Volume:

371.82K

Relative Volume:

0.27

Market Cap:

$483.12M

Revenue:

Net Income/Loss:

$-217.44M

P/E Ratio:

-2.207

EPS:

-1.8486

Net Cash Flow:

$-205.20M

1W Performance:

-0.25%

1M Performance:

+15.95%

6M Performance:

-27.19%

1Y Performance:

-47.82%

1-Day Range:

$3.85

$4.14

1-Week Range:

$3.82

$4.2401

52-Week Range:

$3.28

$9.86

Prime Medicine Inc Stock (PRME) Company Profile

Name

Prime Medicine Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

617-465-0013

Address

60 FIRST ST., CAMBRIDGE

Employee

234

Twitter

Next Earnings Date

Latest SEC Filings

PRME's Discussions on Twitter

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-23	Initiated	Guggenheim	Buy
Apr-18-23	Initiated	Stifel	Buy
Nov-14-22	Initiated	Goldman	Neutral
Nov-14-22	Initiated	JP Morgan	Overweight
Nov-14-22	Initiated	Jefferies	Buy
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight

View All

Prime Medicine Inc Stock (PRME) Latest News

Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024

Oct 27, 2024

Head to Head Review: Prime Medicine (NYSE:PRME) and Invivyd (NASDAQ:IVVD) - Defense World

Oct 27, 2024

Oct 25, 2024

Prime Medicine (NYSE:PRME) Receives Buy Rating from HC Wainwright - MarketBeat

Oct 25, 2024

Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News

Oct 25, 2024

Brokerages Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.50 - Defense World

Oct 25, 2024

Oct 24, 2024

Prime Medicine Presents In Vivo Proof-of-Concept Data - GlobeNewswire

Oct 24, 2024

Prime Medicine Advances Gene Editing for Liver Diseases - TipRanks

Oct 24, 2024

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress - Yahoo Finance

Oct 24, 2024

Oct 22, 2024

Prime Medicine (NYSE:PRME) Shares Down 4.6%Should You Sell? - MarketBeat

Oct 22, 2024

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Oct 22, 2024

Oct 18, 2024

Prime Medicine (NYSE:PRME) Stock Price Up 15%What's Next? - MarketBeat

Oct 18, 2024

Oct 16, 2024

Why I Keep Buying These 14 Incredible Growth Stocks - The Motley Fool

Oct 16, 2024

Oct 15, 2024

There is no doubt that Prime Medicine Inc (PRME) ticks all the boxes. - SETE News

Oct 15, 2024

Prime Medicine to Highlight New Preclinical Data, Including - GlobeNewswire

Oct 15, 2024

Market Watch Highlights: Prime Medicine Inc (PRME) Ends on an Upturn Note at 3.73 - The Dwinnex

Oct 15, 2024

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings - Yahoo Finance

Oct 15, 2024

Oct 14, 2024